TBE-virusrokotteista

•  ROKOTTEISTA

  Tick-borne encephalitis virus vaccines

  
  

  P. Noel Barrett, ... Hartmut J. Ehrlich, in Vaccines (Sixth Edition), 2013

  
  

  Producers

  TBE vaccines are produced commercially by five manufacturers:

   Baxter AG (Vienna), 

  Novartis Vaccines (Marburg),

   IPVE (Moscow), 

  Microgen (Tomsk, Russia), and

   CIBP (Changchun, China). 

  Both manufacturers of European strain vaccines use essentially the same process to produce the vaccine, the major differences being the use of different strains and the addition of different stabilizers. An overview of the characteristics of the European and Russian vaccines is shown in Table 34-2.

  
  

  HSA is used as a stabilizer by Baxter, IPVE, and Microgen, 

  whereas Novartis uses an increased amount of sucrose as a stabilizer

  
  

  . Both manufacturers of European strain vaccines provide 

  adult (Baxter, FSME-IMMUN; Novartis, Encepur) and 

  pediatric (Baxter, FSME-IMMUN Junior; Novartis, Encepur-Children) formulations for children older than 1 year. 

   FSME-IMMUN is marketed as TicoVac in some countries. 

  TBE-Moscow has been approved for use in adults since 1982 and has been used to vaccinate more than 25 million people in Russia and neighboring countries.⁷³

    EnceVir was licensed in the Russian Federation in 2001. Russian manufacturers do not offer pediatric formulations, and neither vaccine is licensed for use in children younger than 3 years. 

  TBE-Moscow has been approved for use in children 3 years or older since 1999.⁷³ 

   EnceVir was administered to children 3 to 16 years old, but this was temporarily stopped by the Russian Ministry of Healthcare in 2010 owing to postvaccination complications.

   No information is available about the manufacturing process, formulation, or dose schedule for the Chinese vaccine, but it is reported to have passed phase 1, 2, and 3 clinical trials.⁷⁶

  Read full chapter

•